The FDA-approved drug Alectinib compromises SARS-CoV-2 nucleocapsid phosphorylation and inhibits viral infection in vitroTomer M. Yaron(Boston Children's Hospital), Nicholas S. Heaton(Duke University)bioRxiv (Cold Spring Harbor Laboratory)August 14, 202010.1101/2020.08.14.251207Cited by 63SaveCiteExport RISWatch citationsRelated PapersAn atlas of substrate specificities for the human serine/threonine kinome|Nature|2023|720Pan-cancer analysis of post-translational modifications reveals shared patterns of protein regulation|Cell|2023|190Pan-cancer proteogenomics connects oncogenic drivers to functional states|Cell|2023|104Pan-cancer proteogenomics characterization of tumor immunity|Cell|2024|91TMEM41B is a host factor required for the replication of diverse coronaviruses including SARS-CoV-2|PLoS Pathogens|2021|62